Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Original

COVID-19 vaccination acceptance in Jambi City, Indonesia: A single vaccination center study

Gilbert Sterling Octavius\textsuperscript{a,⁎}, Theo Audi Yanto\textsuperscript{a}, Rivaldo Steven Heriyanto\textsuperscript{a}, Haviza Nisa\textsuperscript{b}, Catherine Ienawi\textsuperscript{b}, H. Emildan Pasai\textsuperscript{b}

\textsuperscript{a}Department of Internal Medicine, Faculty of Medicine, Universitas Pelita Harapan, Karawaci, Jl. Jend. Sudirman No.20, Bencongan, Kec. Klp. Dua, Kabupaten Tangerang, Banten 15810, Tangerang, Banten, Indonesia
\textsuperscript{b}Puskesmas Putri Ayu, Jambi, Jl. Slamet Riyadi, Legok, Danau Tlk., Kota Jambi, Jambi 36121, Indonesia

Article history:
Received 25 April 2022
Accepted 13 June 2022

Keywords:
COVID-19 vaccination
Vaccine acceptance
Vaccine refusal
Vaccine hesitance
Indonesia

Abstract

Background: Indonesia has not met its vaccination rate target, falling short of 25% in 2021. This study aims to assess all the contributing factors towards vaccine acceptance, hesitance, and refusal in a single vaccination center in Jambi, Indonesia.

Materials and methods: We collected primary data from respondents directly through a structured questionnaire. This was a cross-sectional study with total sampling. We included adults vaccinated for the first dose with CoronaVac in Puskesmas Putri Ayu. The data was collected between March 15th and June 3rd, 2021. Multivariate logistic regression analysis was done to analyse the predictive models.

Results: There are 522 respondents included in this study. Nearly half of the respondents are male (52.1%) and mostly in the age category of 36–45 years old (21.1%). A total of 443 respondents (84.9%) are “vaccine acceptance,” while the rest constitutes “vaccine hesitance and refusal.” Multivariate analysis reveals that respondents who obtain permission from work or school to get vaccinated are more likely to be “vaccine acceptance” with an odds ratio (OR) of 1.76 (95% confidence interval [CI] 1.08–2.91; p-value 0.025), and respondents with ≥2 comorbidities are less likely to be “vaccine acceptance” with an OR of 0.09 (95% CI 0.01–0.64; p-value 0.015).

Conclusions: There is a high vaccine acceptance in this study. Difficulties in getting a work permit and the presence of ≥2 comorbidities decrease the willingness to be vaccinated for COVID-19.

© 2022 Elsevier España, S.L.U. All rights reserved.

Aceptación de la vacuna frente a la COVID-19 en la ciudad de Jambi, Indonesia: estudio de un único centro de vacunación

Resumen

Antecedentes: Indonesia no ha alcanzado su objetivo de tasa de vacunación, por debajo del 25% en 2021. Este estudio tiene como objetivo evaluar todos los factores que contribuyen a la aceptación, la vacilación y el rechazo de la vacuna en un solo centro de vacunación en Jambi, Indonesia.

Palabras clave:
Vacunación COVID-19
Aceptación de la vacuna
Rechazo de la vacuna

⁎ Corresponding author.
E-mail address: gilbert.octavius@lecturer.uph.edu (G.S. Octavius).
https://doi.org/10.1016/j.vacune.2022.10.011
2445-1460/© 2022 Elsevier España, S.L.U. All rights reserved.
Introduction

Vaccination has been touted as a “game-changer” that will help the world return to the “new normal” amid the COVID-19 pandemic.\(^1\) Currently, vaccination status has been implemented nationally in Indonesia and internationally as permission to participate in public activities such as travelling, entering communal spaces (e.g., mall or attending a concert), and going back to work.\(^2,3\)

Although it has been established that COVID-19 vaccines are relatively safe,\(^4-6\) this finding is not widely available when vaccines are freshly distributed. Coupled with misleading information being widespread in the media and scepticism around how fast the COVID-19 vaccine is approved, the number of people being hesitant or even refusing to get a jab skyrockets.\(^7,8\)

By the end of 2021, the government had hoped to have vaccinated around 67% of Indonesians.\(^9\) However, by December 31st 2021, 58.57% of Indonesians had received at least one shot, while only 41.26% of Indonesians were fully vaccinated with two doses.\(^10\) The COVID-19 vaccination effort is being slowed by a lack of competent medical personnel in rural locations, psychological issues, cold-chain storage and distribution challenges, and budgetary issues.\(^11-13\) However, people who are unwilling to be vaccinated or reject vaccines constitute the major issue.\(^14\)

Vaccine hesitance and refusal have been observed worldwide, ranging from lay people to medical personnel.\(^15-17\) In November 2020, the World Health Organisation (WHO), the Ministry of Health of the Republic of Indonesia, and the United Nations Children’s Fund (UNICEF) released a report. The results found that 64.8% of the 112,888 Indonesians polled were willing to be vaccinated, 7.6% refused all vaccines, and 27.6% were undecided.\(^18\) Therefore, it is paramount to assess the possible factors contributing to the high number of vaccine hesitance and vaccine refusal. By converting those hesitant about getting a vaccine, Indonesia could increase its vaccination rate.\(^19\)

This study aims to assess all the contributing factors towards vaccine acceptance, vaccine hesitance, and refusal in a single vaccination center in Jambi, Indonesia. Based on the national survey, Jambi has one of the lowest vaccine acceptance rates of any city in Indonesia.\(^18\) As a result, the findings of this study may shed light on the reasons for poor vaccination acceptance rates.

Methods

We collected primary data from respondents directly through a structured questionnaire. This was a cross-sectional study with total population sampling. This type of sampling is a sort of purposive sampling in which the entire population of interest (i.e., a group of people with the same trait) is researched. The questionnaire consisted of demographic data collection, such as age, sex, ethnicity, religion, marital status, comorbidities, highest education attained, income, health insurance, history of mental disorders, and smoking status. This questionnaire is self-administered, and if respondents were not clear with certain items, they could ask the field workers directly. There were several COVID-19-related questions such as previous exposures or any close contact with COVID-19 patients (yes/no/not sure), the impact of COVID-19 on income (increased/decreased/no change), whether respondents have experienced COVID-19-related symptoms (yes/no) and any COVID-19 testing that had been done (yes/no). We also collected data on height and weight before administering vaccines to calculate body mass index (BMI) and blood pressure to screen for hypertension. The Asia-Pacific classification of BMI would be used to classify BMI.\(^20\)
We included adults (> 18 years) who were vaccinated with CoronaVac (Sinovac Life Sciences, Beijing, China) in Puskesmas Putri Ayu, one of the biggest Puskesmas in Jambi city, Indonesia. Puskesmas are government-mandated community health clinics in Indonesia promoting primary prevention. We chose Puskesmas Putri Ayu as our study site because Puskesmas was the first and only institution to administer COVID-19 vaccines. Being the biggest Puskesmas, this meant that there would be a larger vaccination catchment area compared to other Puskesmas. Our Puskesmas administered vaccines daily and citizens willing to be vaccinated would come to our Puskesmas. Participants were recruited while waiting to be vaccinated. The data was collected between March 15th and June 3rd 2021. The COVID-19 vaccinations were carried out in four phases, where our study period coincided with the second phase of vaccination. The targeted population for this phase was public service officers and the elderly (≥ 60 years old). However, we experienced a lot of unused doses on the field for various reasons such as refusal, not showing up, or contraindicated for the jab. In order to mitigate the number of doses potentially going to waste, residents nearby the Puskesmas were contacted to get the vaccine jab.

Our exclusion criteria were broadly categorised into three: refusal to participate in the study for any reason, contraindicated to COVID-19 vaccine administration, and receiving the second vaccine jab. We initially followed the recommendations of the Indonesian Society of Internal Medicine (issued on March 18th 2021), which was the first institution to recommend who could be vaccinated. Therefore, pregnant women and children were not included in this study as the recommendations to vaccinate these populations were announced on June 22nd 2021, and November 2nd 2021, respectively. Patients with primary immunodeficiency, acute and active infections (including SARS-CoV-2 infections or 3 months post-infection), blood pressure of ≥180/110 mmHg, unstable or uncontrolled chronic conditions, such as diabetes mellitus or heart failure, and those with Fatigue, Resistance, Ambulation, Illness, and Loss of weight (FRAIL) score of >2 were contraindicated to COVID-19 vaccination and hence excluded from this study.

According to the Indonesian Ministry of Health, income was divided into five categories. Poor people had monthly household expenses of less than Rp 1416,000 (~$99); vulnerable people had monthly household expenses of between Rp 1416,000 and Rp 2,128,000 (~$99–$148); aspiring middle-class people had monthly household expenses of between Rp 2,128,001 and Rp 4,800,000 (~$148 to $334); middle-class people had monthly household expenses of between Rp 4,800,001 and Rp 24,000,000 (~$334 to $1671), and upper-class people had monthly household expenses above Rp 24,000,000 (~$1671). Respondents were divided into groups according to their stance on COVID-19 immunisation. We also asked whether respondents obtained permission from their upper management or teachers to be vaccinated that day. The reasoning behind this question was that schools or workplaces sometimes do not accept absence from work or schools just to be vaccinated. Therefore, this might affect one’s acceptance of vaccination. Respondents were grouped as “vaccine acceptance” if they replied yes to the question “Are you ready that you are ready to be vaccinated before arriving at Puskesmas Putri Ayu?”, “vaccine refusal” if they answered no, and “vaccine hesitance” if they answered maybe.

IBM SPSS 26.0 (Statistical Package for the Social Sciences, IBM Corp., Armonk, NY, USA, 2019) was used for statistical analysis. The Kolmogorov–Smirnov test was used to check for normality, and if the p-value was greater than 0.05, the data exhibited a normal distribution. The mean and standard deviation implied that the data were regularly distributed, whereas the median and range implied that the data were not. Bivariate analysis was performed using the chi-square test. Multivariate logistic regression analysis was used to obtain a prediction model with the least confoundings. The receiver operating curve (ROC) and the Hosmer–Lemeshow test would be used to examine the performance of our final prediction findings for discrimination and calibration (goodness of fit), respectively. The ROC will calculate the area under the curve (AUC). An AUC of 1.0 correlates to a perfect result, >0.9 indicates a high accuracy, 0.7–0.9 indicates moderate accuracy, 0.5–0.7 indicates low accuracy, and 0.5 indicates that the results are caused by chance. A p-value of >0.05 from the Hosmer-Lemeshow test would indicate a good calibration.

### Results

There are 522 respondents included in this study (Fig. 1). A majority of our respondent is male (52.1%) and mostly in the age category of 36–45 years old (21.1%) (Table 1). The median BMI falls under the overweight category with 23.8 (13.9–61.3), with 217 respondents (41.6%) belonging to the overweight group. The aspiring middle class dominates with 200 respondents (38.3%) and mostly report no changes in income (77.4%) due to the pandemic. Muslims (64%) and Melayu (33.3%) are our respondents’ most common religion and ethnicity, respectively.

Our respondents are mostly married (73.8%), live together with other family members (92.7%), especially with their children or grandchildren (65.1%). Most of our respondents are highly educated, as 235 respondents (45%) have a minimum of Bachelor’s degrees. This study finds that 468 respondents (89.7%) have at least one insurance, 473 respondents (88.7%) have no comorbidities, and 426 respondents’ family members (78.3%) have no comorbidities. The number of respondents that smoke or had a history of mental disorders is very low, with 24 respondents (4.6%) and eight respondents (1.5%), respectively.

Although the majority (75.3%) claim that no known close contacts are positive for COVID-19 and most respondents (92.5%) never experienced COVID-19 symptoms, 238 respondents (45.6%) have done at least one COVID-19 test. Respondents are mostly independent (60.7%) for registering their vaccination schedule, while 300 respondents (57.5%) do not obtain permission for vaccination. Regarding vaccination stance, 443 respondents (84.9%) are “vaccine acceptance.” Amongst the “vaccine hesitance and refusal” group, the majority is male respondents with 44 respondents (55.7%), married (64 respondents; 81%), non-Chinese (60 respondents; 75.9%), working (61 respondents; 77.2%), lives with another
family member (74 respondents; 93.7%), and lives with children or grandchildren (52 respondents; 65.8%) (results not shown).

Multivariate analysis reveals that respondents who obtain permission from work or school to get vaccinated are more likely to be “vaccine acceptance” with an odds ratio (OR) of 1.76 (95% confidence interval [CI] 1.08–2.91; p-value 0.025), and respondents with two or more comorbidities are less likely to be “vaccine acceptance” with an OR of 0.09 (95% CI 0.01–0.64; p-value 0.015) (Table 2). The Hosmer-Lemeshow test yields a p-value of 0.99 while the AUC is 0.646 (95% CI 0.581–0.711; p-value <0.0001) (Fig. 2). These results indicate that this model has low discrimination with good calibration.

Discussion

Our results indicate that 84.9% of our respondents accept the vaccine. This number is way higher than the previous finding, 65% out of 112,888 respondents, both in Indonesia and Jambi city. One reason that can explain this disparity is that respondents are asked about vaccination stance in the vaccination center, making it more likely that respondents have already accepted vaccination.

From the multivariate analysis, permission to get vaccinated and presence of ≥2 comorbidities are the only significant variables that affect respondents to be “vaccine acceptance”. The reason behind obtaining permission is due to the convenience. People prioritise income even more in the pandemic where unemployment and wage cuts are prevalent. When the study is conducted, vaccines are not mandatory yet. Therefore, obtaining a leave to be vaccinated may be inconvenient as workers might deal with supervisors who are not understanding enough. This finding is also supported by other studies where inconvenience in getting the vaccine is associated with lower uptake. Initially, in the bivariate analysis, getting a permit is not significantly associated with vaccine stance. Confoundings such as occupation, income and the impact of COVID-19 on income may play a role as collider bias.

The first COVID-19 vaccine to be approved at that time still leaves a lot of questions unanswered, such as the safety issues amongst people with comorbidities. This leaves organisations to recommend against vaccinating a certain group of people with specific comorbidities until further evidence is obtained. It is also known that patients with comorbidities are more likely to die from COVID-19 related complications. Therefore, it is natural for patients with comorbidities to decide against being vaccinated. Reasons that may explain this phenomenon include fear of the vaccination side-effects amongst people with comorbidities, poor knowledge about the vaccines, and misinformation regarding COVID-19 vaccines. This finding has also been found in other countries.

Increasing age, male sex, having health insurance, knowing others contract COVID-19, higher income, higher level of education, ethnicities, a large household size, smokers, and mental well-being are some of the factors that are significantly associated with vaccine acceptance in other studies but not in ours. Several reasons may explain these phenomena. Firstly, our study was done during phase two of the national vaccination scheme, where the target populations are public service workers and the elderly. This eliminates the effects of jobs and income towards vaccination stance as it is made mandatory for public service workers to get a vaccination jab by the government.

One study finds that instructions from supervisors or the
Table 1 – Demographics of respondents.

| Variables                        | N   | %    |
|----------------------------------|-----|------|
| Gender                           |     |      |
| Male                             | 272 | 52.1 |
| Female                           | 250 | 47.9 |
| Age - Median (range)              |     |      |
| >65                              | 60  | 11.5 |
| 56-65                            | 69  | 13.2 |
| 46-55                            | 106 | 20.3 |
| 36-45                            | 110 | 21.1 |
| 26-35                            | 104 | 19.9 |
| 18-25                            | 73  | 14.0 |
| BMI- Median (range)               |     |      |
| Normal                           | 178 | 34.1 |
| Obese                            | 98  | 18.8 |
| Overweight                       | 217 | 41.6 |
| Underweight                      | 29  | 5.6  |
| Marriage status                  |     |      |
| Married                          | 385 | 73.8 |
| Not Married (including divorced) | 137 | 26.2 |
| Occupation                       |     |      |
| Entrepreneur                     | 166 | 32   |
| Public service officer           | 108 | 20.6 |
| Healthcare worker                | 14  | 2.7  |
| Housewife                        | 37  | 7.1  |
| Religious leader                 | 12  | 2.3  |
| Student/Jobless/Retired          | 115 | 22   |
| Teaching staff                   | 50  | 9.5  |
| Others                           | 20  | 3.8  |
| Ethnicity                        |     |      |
| Batakese                         | 26  | 5.0  |
| Javanese                         | 98  | 18.8 |
| Melayu                           | 174 | 33.3 |
| Minangkabau                      | 36  | 6.9  |
| Chinese                          | 159 | 30.5 |
| Others                           | 29  | 5.5  |
| Permission from workplace/school to be vaccinated today |     |      |
| No                               | 300 | 57.5 |
| Yes                              | 222 | 42.5 |
| Monthly income                   |     |      |
| <Rp. 1416,000                    | 95  | 18.2 |
| Rp. 1416,001–2,128,000           | 109 | 20.9 |
| Rp. 2,128,001–4800,00            | 200 | 38.3 |
| Rp. 4800,001–24,000,000          | 116 | 22.2 |
| >Rp. 24,000,000                  | 2   | 0.4  |
| Religion                         |     |      |
| Buddhist                         | 103 | 19.7 |
| Muslim                           | 334 | 64.0 |
| Catholic                         | 12  | 2.3  |
| Kong Hu Chu                      | 19  | 3.6  |
| Christian                        | 54  | 10.3 |
| Education                        |     |      |
| D3 or equivalent                 | 32  | 6.1  |
| Bachelor’s/Master’s/Doctoral degree | 235 | 45   |
| Primary school or equivalent     | 24  | 4.6  |
| Secondary school or equivalent   | 28  | 5.6  |
| High school or equivalent        | 189 | 35.4 |
| Did not finish primary school    | 14  | 2.7  |
| COVID-19 impact on income        |     |      |
| Increased income                 | 12  | 2.3  |
| Decreased income                 | 106 | 20.3 |
| No impact                        | 404 | 77.4 |
| Insurance                        |     |      |
| Own an insurance                 | 468 | 89.7 |
| Does not have an insurance       | 54  | 10.3 |

Table 1 (Continued)

| Variables                        | N   | %    |
|----------------------------------|-----|------|
| Whom do you live with?           |     |      |
| Alone                            | 38  | 7.3  |
| With other family members        | 484 | 92.7 |
| Are you living with children/grandchildren in your house? (N = 484) |     |      |
| No                               | 169 | 34.9 |
| Yes                              | 315 | 65.1 |
| Known positive COVID-19 tests amongst close contacts |     |      |
| No                               | 393 | 79.3 |
| Not sure                         | 87  | 16.7 |
| Yes                              | 42  | 8.3  |
| Have you ever done a COVID-19 test? |     |      |
| No                               | 284 | 54.4 |
| Yes                              | 238 | 45.6 |
| Ever experienced COVID-19 symptoms (fever, malaise, cough) |     |      |
| No                               | 483 | 92.5 |
| Yes                              | 39  | 7.5  |
| Who registered you for a COVID-19 vaccine appointment? |     |      |
| Myself                           | 317 | 60.7 |
| Others                           | 205 | 39.3 |
| Comorbidity*                     |     |      |
| Asthma                           | 8   | 1.5  |
| Hypertension                     | 29  | 5.4  |
| Diabetes                         | 16  | 3.2  |
| Others                           | 7   | 1.4  |
| No Comorbidities                 | 473 | 88.7 |
| Comorbidities amongst family members* |     |      |
| Asthma                           | 9   | 1.7  |
| Hypertension                     | 38  | 7.6  |
| Diabetes                         | 51  | 9.4  |
| Others                           | 20  | 3.6  |
| No Comorbidities                 | 426 | 78.3 |
| History of mental disorders      |     |      |
| No                               | 514 | 98.5 |
| Yes                              | 8   | 1.5  |
| Smoking status                   |     |      |
| No                               | 498 | 95.4 |
| Yes                              | 24  | 4.6  |
| Vaccination stance               |     |      |
| Vaccine acceptance               | 443 | 84.9 |
| Vaccine hesitance and refusal    | 79  | 15.1 |

* One respondent can present with more than one comorbid.

This might downplay the impacts of age and sex, and the population studied need to be vaccinated per government mandate. The second reason is because vaccinations are given for free in every Puskesmas. Therefore, having a medical insurance and income might not affect vaccine acceptance. As for the history of mental health, one study in China finds that vaccine acceptance amongst people with and without mental disorders are similar. The difference lies in their willingness to pay for the vaccine. Lastly, the effects of living with other family members or smoking on vaccine acceptance may be mediated by people with ≥2 comorbidities. People are more willing to be vaccinated so that they can protect themselves and their loved ones.
| Variables                        | OR   | 95% CI       | p-value | Adjusted OR | 95% CI       | p-value |
|---------------------------------|------|--------------|---------|-------------|--------------|---------|
| Gender                          |      |              |         |             |              |         |
| Male                            | 0.84 | 0.52–1.37    | 0.568   | –           |              |         |
| Female                          |      |              |         |             |              |         |
| Age                             |      |              |         |             |              |         |
| >65                             | Ref  | Ref          | Ref     | –           |              |         |
| 56–65                           | 2.13 | 0.84–5.35    | 0.162   | –           |              |         |
| 46–55                           | 1.6  | 0.66–3.89    | 0.399   | –           |              |         |
| 36–45                           | 0.95 | 0.37–2.41    | 1       | –           |              |         |
| 26–35                           | 0.93 | 0.36–2.39    | 1       | –           |              |         |
| 18–25                           | 0.58 | 0.19–1.78    | 0.501   | –           |              |         |
| BMI                             |      |              |         |             |              |         |
| Normoweight                     | Ref  | Ref          | Ref     | –           |              |         |
| Underweight                     | 0.94 | 0.3–2.91     | 1       | –           |              |         |
| Overweight                      | 1.01 | 0.58–1.77    | 1       | –           |              |         |
| Obese                           | 1.23 | 0.63–2.39    | 0.669   | –           |              |         |
| Marriage                        |      |              |         |             |              |         |
| Married                         | 0.62 | 0.34–1.12    | 0.146   | –           |              |         |
| Not Married                     |      |              |         |             |              |         |
| Occupation                      |      |              |         |             |              |         |
| Working                         | 0.67 | 0.38–1.2     | 0.212   | –           |              |         |
| Not Working                     |      |              |         |             |              |         |
| Ethnicity                       |      |              |         |             |              |         |
| Chinese                         | 1.46 | 0.84–2.54    | 0.226   | –           |              |         |
| Non-Chinese                     |      |              |         |             |              |         |
| Permission                      |      |              |         |             |              |         |
| Yes                             | 0.6  | 0.37–0.98    | 0.051   | 1.76        | 1.08–2.91    | 0.025   |
| No                              |      |              |         |             |              |         |
| Income                          |      |              |         |             |              |         |
| Aspiring Middle Class           | Ref  | Ref          | Ref     | –           |              |         |
| Poor                            | 0.93 | 0.45–1.92    | 0.983   | –           |              |         |
| Vulnerable                      | 1.53 | 0.82–2.86    | 0.241   | –           |              |         |
| Middle Class                    | 1.18 | 0.62–2.25    | 0.743   | –           |              |         |
| Upper Class                     | 6.41 | 0.39–105.51  | 0.647   | –           |              |         |
| Religion                        |      |              |         |             |              |         |
| Muslim                          | 0.69 | 0.41–1.17    | 0.208   | –           |              |         |
| Non-Muslim                      |      |              |         |             |              |         |
| Education                       |      |              |         |             |              |         |
| Bachelor’s/Master’s/Doctoral degree | Ref | Ref          | Ref     | –           |              |         |
| D3 or equivalent                | 5.61 | 0.74–42.39   | 0.11    | 1.95        | 0.25–15.65   | 0.526   |
| Highschool or equivalent        | 1.04 | 0.62–1.77    | 0.983   | 0.34        | 0.02–5.96    | 0.461   |
| Secondary school or equivalent  | 2.21 | 0.91–5.4     | 0.132   | 2.15        | 0.27–17.24   | 0.471   |
| Primary school or equivalent    | 0.79 | 0.22–2.79    | 0.496   | 5.1         | 0.56–46.1    | 0.148   |
| Did not finish primary school   | 0.43 | 0.05–3.35    | 0.355   | 1.92        | 0.18–20.61   | 0.592   |
| COVID-19 impact                 |      |              |         |             |              |         |
| No impact (or does not have a job) | Ref | Ref          | Ref     | –           |              |         |
| Decreased income                | 0.98 | 0.54–1.89    | 1       | –           |              |         |
| Increased income                | 0.52 | 0.14–1.99    | 0.577   | –           |              |         |
| Insurance                       |      |              |         |             |              |         |
| Insured                         | 0.82 | 0.36–1.89    | 0.787   | –           |              |         |
| Not Insured                     |      |              |         |             |              |         |
| Living alone or together        |      |              |         |             |              |         |
| Together                        | 0.84 | 0.32–2.22    | 0.906   | –           |              |         |
| Alone                           |      |              |         |             |              |         |
| Living with kids                |      |              |         |             |              |         |
| Yes                             | 0.76 | 0.46–1.25    | 0.339   | –           |              |         |
| No                              |      |              |         |             |              |         |
| Family/friends contracted COVID-19 | Ref | Ref          | Ref     | –           |              |         |
| Yes                             | 1.13 | 0.48–2.67    | 0.954   | –           |              |         |
| No                              | 1.14 | 0.42–3.1     | 1       | –           |              |         |
| COVID-19 test                   |      |              |         |             |              |         |
| Yes                             | 1.06 | 0.66–1.72    | 0.899   | –           |              |         |
| No                              |      |              |         |             |              |         |

(Continúa)
Our studies suffer from several limitations. Firstly, vaccination policies change according to the COVID-19 situation in Indonesia and rapid advancement in the knowledge of the COVID-19 vaccine. During the timeframe of our study, vaccination for pregnant women and children is not yet made available; thus, the vaccine acceptance might be falsely high in our study.\(^4^9\)–\(^5^1\) Secondly, the study is conducted in a single-center where respondents are vaccinated. Therefore, it falsely elevates the vaccine acceptance rate compared to surveying the general population online.\(^1^8\) The third limitation is that our study has a poor discriminant. This finding suggests that other predictive variables not explored in our study may affect vaccine acceptance. Lastly, our study only achieves a 37.3% (522/1400) response rate, introducing a non-response bias.\(^5^2\)

Despite some limitations, our study has some merits as well. Amongst other studies that look into vaccine acceptance in Indonesia,\(^5^3\)–\(^5^6\) our study is one of the few studies conducted in person. Therefore, our study does not suffer from the limitations introduced by web-based surveys, such as sampling issues and responder bias.\(^5^7\),\(^5^8\) The other strength of this study is a high vaccination acceptance rate. This may guide the government to tailor their policies, such as allowing permit leave to be vaccinated and launching an awareness campaign for people with comorbidities to feel safe to get a jab. Lastly, our study ends before COVID-19 is made compulsory for anyone. Failure to be vaccinated results in not travelling, going to public spaces, or even working.\(^5^9\) Conducting a study might introduce a bias in the vaccination

### Table 2 (Continued)

| Variables                   | OR   | 95% CI | p-value | Adjusted OR | 95% CI | p-value |
|-----------------------------|------|--------|---------|-------------|--------|---------|
| Vaccine registration        |      |        |         |             |        |         |
| Myself                      | 1.06 | 0.65–1.73 | 0.905 | –           |        |         |
| Other                       |      |         |         |             |        |         |
| Self Comorbid               |      |        |         |             |        |         |
| None                        |      |         |         |             |        |         |
| 1 Comorbid                  | 0.43 | 0.13–1.44 | 0.24  | 0.23        | 0.05–1.043 | 0.057 |
| ≥2 Comorbs                  | 3.29 | 0.77–14.06 | 0.117 | 0.09        | 0.01–0.64 | 0.015 |
| Family Comorbid             |      |        |         |             |        |         |
| None                        |      |         |         |             |        |         |
| 1 Comorbid                  | 1.21 | 0.62–2.39 | 0.705 | –           |        |         |
| >2 Comorbs                  | 1.002 | 0.34–2.3 | 0.586 | –           |        |         |
| History of Mental Disorder  |      |        |         |             |        |         |
| Yes                         |      |         |         |             |        |         |
| Smoking                     |      |        |         |             |        |         |
| Yes                         | 1.18 | 1.14–1.23 | 0.614 | –           |        |         |
| No                          | 0.89 | 0.3–2.67  | 0.773 | –           |        |         |

![Fig. 2](image-url) – The receiver operating curve to assess discrimination of the multivariate model of vaccine acceptance.
stance as vaccines are made the prerequisite to allow people to do their regular activities normally.

Conclusion

There is a high vaccine acceptance in this study. Difficulties in getting a work permit and the presence of ≥2 comorbidities decrease the willingness to be vaccinated for COVID-19. The government, therefore, needs to play a role in ensuring that companies or workplaces do not punish employees for taking a leave to be vaccinated. A collaboration with healthcare workers is also needed to educate Indonesians that the vaccine is safe for people with comorbidities as long as no contraindications are present. In this manner, the vaccine acceptance rate may be increased, especially when the booster jab is implemented soon.

Ethics approval and consent to participate

The Faculty of Medicine Universitas Pelita Harapan granted this study's ethical permission with an approval number of 155/K-LKJ/ETIK/VI/2021.

Availability of data and materials

Available upon request.

Funding

The authors declare that the research was conducted in the absence of any financial grants.

Authors’ contributions

GSO, HEP, and TAY did the conception of this research. Data collections and cleaning are done by GSO, HN, and CI. Statistical analysis were done by GSO and RSH. GSO, RSH, HN, and CI drafted the article while TAY and HEP did critical revision of the article. Final approval of the version to be published was granted by all authors.

Conflict of interest

The authors declare no conflict of interest.

Acknowledgements

We would want to express our gratitude to the vaccination team of Puskesmas Putri Ayu for doing such a good gesture and assisting us with our research. The authors declare that the research was conducted in the absence of any financial grants.

References

1. Chen LH, Petersen E, Blumberg L, Piyaphanee W, Steffen R. COVID-19 health passes: current status and prospects for a global approach. J Travel Med. 2021;28(7) taab118.
2. Petersen E, Lucey D, Blumberg L, Kramer LD, Al-Abri S, Lee SS, et al. COVID-19 vaccines under the International Health Regulations—We must use the WHO international certificate of vaccination or prophylaxis. International Journal of Infectious Diseases. IJID. 2021;104:175–7.
3. Pavli A, Maltezou HC. COVID-19 vaccine passport for safe resumption of travel. J Travel Med. 2021;28(4).
4. Barda N, Dagan N, Ben-Shlomo Y, Kepten E, Waxman J, Ohana R, et al. Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting. New England Journal of Medicine. 2021;385(12):1078-90.
5. Wu Q, Dudley MZ, Chen X, Bai X, Dong K, Zhuang T, et al. Evaluation of the safety profile of COVID-19 vaccines: a rapid review. BMC Med. 2021;19(1):173.
6. Munro APS, Janani L, Cornelius V, Aley PK, Babbage G, Baxter D, et al. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCoV-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. The Lancet. 2021;398(10318):2258–76.
7. Lazarus JV, Ratzan SC, Palayew A, Gostin LO, Larson HJ, Rabin K, et al. A global survey of potential acceptance of a COVID-19 vaccine. Nat Med. 2021;27(2):225–8.
8. Loomba S, de Figueiredo A, Palayew A, Graaf K, Larson HJ. Measuring the impact of COVID-19 vaccine misinformation on vaccination intent in the UK and USA. Nat Hum Behav. 2021;5(3):337–48.
9. United Nations Children's Fund. Indonesia COVID-19 Response Situation Report 2021 [cited 2021 August 12th]. Available from: https://reliefweb.int/sites/reliefweb.int/files/resources/UNICEF%20Indonesia%20COVID-19%20Situation%20Report%20-%20April%202021.pdf.
10. COVIDVax. Live COVID-19 Vaccination Tracker: Indonesia 2022 [cited 2022 January 15th]. Available from: https://covidvax.live/location/idn.
11. Fonjungo F, Banerjee D, Abdulah R, Diantini A, Kusuma ASW, Permana MY, et al. Sustainable financing for new vaccines in Indonesia: challenges and strategies. Sustainability. 2020;12(21).
12. Yanto TA, Octavius GS, Heriyantri RS, Jenawi C, Nisa H, Pasai HE. Psychological factors affecting COVID-19 vaccine acceptance in Indonesia. The Egyptian Journal of Neurology, Psychiatry and Neurosurgery. 2021;57(1):177.
13. Octavius GS, Antonio F. Antecedents of intention to adopt mobile health (mHealth) application and its impact on intention to recommend: an evidence from Indonesian customers. Int J Telemed Appl. 2021;2021:6698627.
14. Cascini F, Pantovic A, Al-Ajlouni Y, Failla G, Ricciardi W. Attitudes, acceptance and hesitancy among the general population worldwide to receive the COVID-19 vaccines and their contributing factors: a systematic review. EClinicalMedicine. 2021;40, 101113.
15. Dzieciolowska S, Hamel D, Gadio S, Dionne M, Gagnon D, Robitaille L, et al. Covid-19 vaccine acceptance, hesitancy, and refusal among Canadian healthcare workers: a multicenter survey. Am J Infect Control. 2021;49(9):1152–7.
16. Fridman A, Gershon R, Gneezy A. COVID-19 and vaccine hesitancy: A longitudinal study. Plos One. 2021;16(4), e0250123
17. Trogen B, Pirosfki L-A. Understanding vaccine hesitancy in COVID-19. Med (N Y). 2021;2(5):498–501.
18. The Ministry of Health, NITAG, UNICEF, and, WHO. COVID-19 Vaccine Acceptance Survey in Indonesia 2020 [cited 2021 August 12th]. Available from: https://covid19.go.id/storage/app/media/Hasil%20Kajian%202020/Vaccine-acceptance-survey-en-12-11-2020final.pdf.
19. Shen SC, Dubey V. Addressing vaccine hesitancy: Clinical guidance for primary care physicians working with parents. Can Fam Physician. 2019;65(3):175–81.
20. Lim JU, Lee JH, Kim JS, Hwang YI, Kim T-H, Lim SY, et al. Comparison of World Health Organization and Asia-Pacific body mass index classifications in COPD patients. Int J Chron Obstruct Pulmon Dis. 2017;12:2465–75.
21. Muhyyiddin Nugroho H. A year of Covid-19: a long road to recovery and acceleration of Indonesia’s development. The Indonesian Journal of Development Planning. 2021;5:1–19.
22. Indonesian Society of Internal Medicine. Rekomendasi PAPDI tentang Pemberian Vaksinasi COVID-19 pada Pasien dengan Penyakit Penyerta/ Komorbid (Revisi 18 Maret 2021) [cited 2021 August 12th]. Available from: https://www.papdi.or.id/berita/info-papdi/1024-rekomendasi-papdi-tentang-pemberian-vaksinasi-covid-19-pada-pasien-dengan-penyakit-penyerta-komorbid-revisi-18-maret-2021; 2021.
23. Indonesian Society of Obstetrics and Gynecology. Rekomendasi POGI terkait dengan melonjaknya kasus ibu hamil dengan Covid-19 dan perlindungan terhadap tenaga kesehatan [cited 2022 12th January]. Available from: https://pogii.or.id/publish/wp-content/uploads/2021/06/Revisi-Rekomendasi-POGI-utk-Bumil-dengan-Covid-19-.pdf.
24. Indonesian Pediatric Society. Rekomendasi Ikatan Dokter Anak Indonesia Pemberian Vaksin COVID-19 (Coronavac®) pada Anak Usia 6-11 Tahun Pemutakhiran 16 Desember 2021 [cited 2022 12th January]. Available from: https://www.idasi.or.id/tentang-idai/pernyataan-idai/rekomendasi-ikatan-dokter-anak-indonesia-pemberian-vaksin-covid-19-coronavac%C2%AE-pada-anak-usia-6-11-tahun-pemutakhiran-16-desember-2021; 2021.
25. Fischer JE, Bachmann LM, Jaeschke R. A readers’ guide to the interpretation of diagnostic test properties: clinical example of sepsis. Intensive Care Med. 2003;29(7):1043–51.
26. Zou KH, O’Malley AJ, Mauri L. Receiver-operating characteristic analysis for evaluating diagnostic tests and predictive models. Circulation. 2007;115(5):654–7.
27. Leelavathy M, Messaline S, Ramachandran D, Sukumaran A, Jose R, Noufel AN. Attitude towards COVID-19 vaccination among the public in Kerala: A cross sectional study. Journal of Family Medicine and Primary Care. 2021;10(1).
28. Ngheim N, Wilson N. Potential impact of COVID-19 related unemployment on increased cardiovascular disease in a high-income country: modeling health loss, cost and equity. PLOS ONE. 2021;16(5), e0246053
29. Jacob C, Kristin K, Giselis C, van Allen Z, Jeremy G, Justin P. Factors affecting COVID-19 vaccination acceptance and uptake among the general public: a living behavioural science evidence synthesis (v1.0, Apr 30th , 2021) [cited 2022 12th August]. Available from: https://www.mcmasterforum.org/docs/default-source/product-documents/living-evidence-syntheses/covid-19-living-evidence-synthesis-4.1—factors-affecting-covid-19-vaccination-acceptance-and-uptake-among-the-general-public.pdf?sfvrsn=5368712f_7; 2021.
30. Griffith GJ, Morris TT, Tuddall MJ, Herbert A, Mancano G, Pike L, et al. Collider bias undermines our understanding of COVID-19 disease risk and severity. Nat Commun. 2020;11(1):5749.
31. Choi WS, Cheong HJ. COVID-19 vaccination for people with comorbidities. Infect Chemother. 2021;53(1):155–8.
32. Motos A, López-Gavín A, Riera J, Ceccato A, Fernández-Barat L, Bermejo-Martín JF, et al. Higher frequency of comorbidities in fully vaccinated patients admitted to icu due to severe covid-19: a prospective, multicenter, observational study. Eur Respir J. 2021;2102275.
33. Reno C, Maietti E, Fantini MP, Savoia E, Manzoli L, Montalti M, et al. Enhancing COVID-19 vaccines acceptance: results from a survey on vaccine Hesitancy in Northern Italy. Vaccines. 2021;9(4).
34. Ruiz JB, Bell RA. Predictors of intention to vaccinate against COVID-19: Results of a nationwide survey. Vaccine. 2021;39(7):1080–6.
35. Chew NWS, Cheong C, Kong G, Phua K, Ngiam JN, Tan BYQ, et al. An Asia-Pacific study on healthcare workers’ perceptions of, and willingness to receive, the COVID-19 vaccination. Int J Infect Dis. 2021;106:52–60.
36. Mohamed NA, Solehan HM, Mohd Rani MD, Ithnin M, Che Isahak CI. Knowledge, acceptance and perception on COVID-19 vaccine among Malaysians: A web-based study. Plos One. 2021;16(8), e0256110.
37. Hawlader MDH, Rahman ML, Nazir A, Ara T, Haque MMA, Saha S, et al. COVID-19 vaccine acceptance in South Asia: a cross-country study from http://www.ijidonline.com. International Journal of Infectious Diseases: IJID. 2022;114:1–10.
38. Kelly BJ, Southwell BG, McCormack LA, Bann CM, MacDonald PDM, Frazier AM, et al. Predictors of willingness to get a COVID-19 vaccine in the U.S. BMC Infect Dis. 2021;21(1):338.
39. Dorman C, Perera A, Condon C, Chau C, Qian J, Kalk K, et al. Factors associated with willingness to be vaccinated against COVID-19 in a large convenience sample. J Community Health. 2021;46(5):1013–9.
40. Mustapha M, Lawal BK, Sha’aban A, Jatau AI, Wada AS, Bala AA, et al. Factors associated with acceptance of COVID-19 vaccine among University health sciences students in Northwest Nigeria. Plos One. 2021;16(11) e0260672.
41. Valckx S, Crévecoeur J, Verelst F, Vranckx M, Hendrickx G, Hens N, et al. Individual factors influencing COVID-19 vaccine acceptance in between and during pandemic waves (July–December 2020). Vaccine. 2022;40(1):151–61.
42. Bongomin F, Olum R, Andia-Biraro I, Nakwagala FN, Hassan KH, Nassozi DR, et al. COVID-19 vaccine acceptance among high-risk populations in Uganda. Therapeutic Advances in Infectious Disease. 2021;8 20493661211024376.
43. Berihun G, Walle Z, Berhanu L, Teshome D. Acceptance of COVID-19 vaccine and determinant factors among patients with chronic disease visiting desse comprehensive specialized hospital, Northeastern Ethiopia. Patient Preference and Adherence. 2021;15:1795–805.
44. Bono SA, de Moura Faria, Villela E, Siau CS, Chen WS, Pengpid S, Hassan MT, et al. Factors affecting COVID-19 vaccine acceptance: an international survey among low- and middle-income countries. Vaccines. 2021;9(5).
45. Jackson SE, Paul E, Brown J, Steptoe A, Fancourt D. Negative vaccine attitudes and intentions to vaccinate against Covid-19 in relation to smoking status: a population survey of UK adults. Nicotine Tob Res. 2021;23(9):1623–8.
46. Krebs NM, D’Souza G, Bordiner C, Allen SJ, Hobbirk AL, Foulds J, et al. COVID-19 vaccination uptake and hesitancy among current tobacco users. Tobacco Use Insights. 2021;14 1179173X211068027.
47. El-Elmat T, AbuAlSamen MM, Almomami BA, Al-Sawalha NA, Alali FQ. Acceptance and attitudes toward COVID-19 vaccines: A cross-sectional study from Jordan. Plos One. 2021;16(4), e0250555.
48. Hao F, Wang B, Tan W, Husain SF, McIntyre RS, Tang X, et al. Attitudes toward COVID-19 vaccination and willingness to pay: comparison of people with and without mental disorders in China. BJPsych Open. 2021;7(5), e146.
49. Nguyen LH, Hoang MT, Nguyen LD, Ninh LT, Nguyen HTT, Nguyen AD, et al. Acceptance and willingness to pay for COVID-19 vaccines among pregnant women in Vietnam. Trop Med Int Health. 2021;26(10):1303–13.

50. Skjefte M, Ngirbabul M, Akeju O, Escudero D, Hernandez-Diaz S, Wyszynski DF, et al. COVID-19 vaccine acceptance among pregnant women and mothers of young children: results of a survey in 16 countries. Eur J Epidemiol. 2021;36(2):197–211.

51. Alfieri NL, Kusma JD, Heard-Garris N, Davis MM, Golbeck E, Barrera L, et al. Parental COVID-19 vaccine hesitancy for children: vulnerability in an urban hotspot. BMC Public Health. 2021;21(1):1662.

52. Sedgwick P. Non-response bias versus response bias. BMJ. British Medical Journal. 2014;348, g2573.

53. Faturohman T, Kengsiswoyo GAN, Harapan H, Zailani S, Rahadi RA, Arief NN. Factors influencing COVID-19 vaccine acceptance in Indonesia: an adoption of technology acceptance model. F1000Res. 2021;10:476.

54. Harapan H, Wagner AL, Yufika A, Winardi W, Anwar S, Gan AK, et al. Acceptance of a COVID-19 vaccine in Southeast Asia: a cross-sectional study in Indonesia. Frontiers in Public Health. 2020;8:381.

55. Wirawan GBS, Mahardani PNTY, Cahyani MRK, Laksmi NLPSP, Januraga PP. Conspiracy beliefs and trust as determinants of COVID-19 vaccine acceptance in Bali, Indonesia: Cross-sectional study. Personal Individ Differ. 2021;180:110995.

56. Susilawaty A, Noviyanto F, Afrianty I, Syahputra A, Kurniasari L, Handoko L, et al. Attitude, risk perception and public acceptance against Coronavirus Disease 2019 Vaccination in Indonesia. Open Access Macedonian. J Med Sci. 2021;9(E):717–21.

57. Andrade C. The limitations of online surveys. Indian J Psychol Med. 2020;42(6):575–6.

58. Wright KB. Researching internet-based populations: advantages and disadvantages of online survey research, online questionnaire authoring software packages, and web survey services. Journal of Computer-Mediated Communication. 2005;10(3) JCMC1034.

59. Aini M. Mandatory Coronavirus Disease-19 (Covid-19) Vaccination in Indonesia: legal aspect. Journal of Legal, Ethical and Regulatory Issues. 2021;24(Special Issue 1):1–15.